LEXX (Lexaria Bioscience) Tariff Resilience Score: 8/10 (As of Jul. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LEXX Lexaria Bioscience Corp LEXX
22 GF Score
Price $0.54
GF Value $0.37
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Lexaria Bioscience Tariff Resilience Score?

Lexaria Bioscience LEXX +3.69% 22 Tariff Resilience Score is 8 as of Jul. 28, 2026. GuruFocus rates LEXX with a GF Score™ of 22/100 and a GF Value™ of $0.37 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,367 Biotechnology companies, Lexaria Bioscience ranks better than 98.68% on this metric.

Lexaria Bioscience has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Lexaria Bioscience has Lexaria Bioscience has limited exposure to tariffs as its operations are primarily focused on domestic markets. Its innovative technology and niche market position provide resilience against international trade fluctuations.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Lexaria Bioscience might have Highly Resilient.

Lexaria Bioscience  (NAS:LEXX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Lexaria Bioscience Tariff Resilience Score Related Terms

LEXX vs CTXR, PTN, HIND: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Lexaria Bioscience's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lexaria Bioscience Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's Tariff Resilience Score falls into.


LEXX
22GF Score
Lexaria Bioscience Corp LEXX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Lexaria Bioscience (LEXX) has a Tariff Resilience Score of 8 as of Jul. 28, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Lexaria Bioscience ranks #18 out of 1367 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Lexaria Bioscience's Tariff Resilience Score too high?
Lexaria Bioscience's current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Lexaria Bioscience's value of 8 is 100% above this industry median. Based on the distribution chart, Lexaria Bioscience ranks #18 out of 1367 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lexaria Bioscience has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's Tariff Resilience Score compare to CTXR and PTN?
According to the Biotechnology industry distribution chart, Lexaria Bioscience ranks #18 out of 1367 companies for Tariff Resilience Score. This places Lexaria Bioscience in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Lexaria Bioscience's value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,367 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lexaria Bioscience's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lexaria Bioscience's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.37, compared to a current price of $0.54 — trading 46% above its estimated fair value. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Lexaria Bioscience's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current Tariff Resilience Score is 8 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lexaria Bioscience (LEXX) Overvalued in 2026?

Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be overvalued. The current stock price of $0.54 is trading 46% above its estimated GF Value™ of $0.37. GuruFocus considers Lexaria Bioscience to be Significantly Overvalued.

Key valuation signals for LEXX:

  • Tariff Resilience Score: 8
  • GF Value™: $0.37 vs. price of $0.54 (46% above fair value)
  • GF Score™: 22/100 with 4 warning signs
  • Industry Position: 100% above the Biotechnology median (#18 of 1367)

No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lexaria Bioscience Business Description

Address 740 McCurdy Road, No. 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
22GF Score

Get the complete analysis for LEXX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.54
Price
$0.37
GF Value